ADMP News and Press, Adamis Pharmaceuticals Corporation From 02/28/22

Adamis Pharmaceuticals (ADMP +1.9%) said the Data Safety Monitoring Board (DSMB) determined that its phase 2/3 trial of Tempol to treat COVID-19 can continue as no safety or clinical concerns were seen following acceleration of patient enrollment in the study. The data from the first 50 ...

SAN DIEGO, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammato...

Are These Penny Stocks on Your Watchlist Right Now? On January 10th, we saw penny stocks and blue chips underperform, keeping a five-day losing streak going. While this is not out of the ordinary, it is definitely not desired for those who invest in penny stocks or any securities fo...

Adamis Pharmaceuticals has two FDA-approved products and a potential blockbuster drug in TEMPOL. However, the company has a long history of blunders that have devastated the share price. I believe the company has a chance to make 2022 a turnaround year, but it is going to require maki...

3 Penny Stocks to Watch Under $1 in December With December here, penny stocks continue to show renewed momentum. Although trading both penny stocks and blue chips has been difficult in the last few months and especially the past week or so, investors are eager to find small-caps tha...

SAN DIEGO, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that additional data in a quantitative systems pharmacology model supports the dose of naloxone hydrochloride that is included in the company’s ZIMHI™ (naloxo...

Adamis Pharmaceuticals (NASDAQ:ADMP) trade low, down 8%, despite regaining Nasdaq compliance. The company had received the letter as it failed to file for quarterly reports, Form 10-Q for the periods ended March 31, 2021, June 30, 2021 and September 30, 2021. For further details see: Ad...

SAN DIEGO, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it has received a letter...

Adamis Pharmaceuticals Corporation (ADMP) Q3 2021 Earnings Conference Call November 22, 2021 05:00 AM ET Company Participants Robert Uhl – Chief Accounting Officer Dennis Carlo – CEO Ron Moss – Chief Medical Officer David Marguglio – Chief Business Officer David Be...

SAN DIEGO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced financial results for the nin...